HDAC3 and neoplasm: At four weeks post inoculation, mice bearing HDAC3 KO tumor showed impaired engraftment (50% vs. 25% non-engrafted tumor in HDAC3 KO and HDAC3 WT group, respectively) and decreased tumor burden (mean total flux 1.1e7 vs. 2.9e9 in HDAC3 KO and WT, respectively), (Figs. 6b, c).